Adnamil, 100 mg, tablets
Adnamil, 300 mg, tablets
Allopurinol
Allopurinol, the active substance of Adnamil, and its main metabolite oxypurinol, reduce the concentration of uric acid in serum and urine by inhibiting the activity of xanthine oxidase, an enzyme that catalyzes the oxidation of hypoxanthine to xanthine and xanthine to uric acid.
Taking Adnamil is indicated to reduce the production of uric acid in diseases where its deposition has already occurred (e.g., gouty arthritis, gouty tophi, kidney stones) or in clinical conditions where there is such a risk (e.g., cancer treatment potentially leading to acute uric acid nephropathy).
The main clinical conditions where uric acid deposition may occur are:
Adnamil is indicated for the treatment of kidney stones with 2,8-dihydroxyadenine (2,8-DHA) stones, resulting from decreased activity of adenine phosphoribosyltransferase.
Adnamil is indicated for the treatment of recurrent kidney stones, with mixed calcium oxalate stones, with accompanying hyperuricosuria, in cases where dietary, fluid, and other treatments have been ineffective.
Before starting to take Adnamil, discuss it with your doctor or pharmacist if you:
If you are unsure whether any of the above applies to you, consult your doctor or pharmacist before taking allopurinol.
During treatment with allopurinol, severe skin reactions have been reported, including hypersensitivity syndrome, Stevens-Johnson syndrome, and toxic epidermal necrolysis.
Often, the rash can involve ulcers of the mouth, throat, nose, genitals, and conjunctivitis (red and swollen eyes). Such severe skin reactions are often preceded by symptoms similar to the flu, such as fever, headache, body aches (so-called flu-like symptoms). The rash may progress, leading to the formation of blisters and peeling of the skin. Such severe skin reactions may occur more frequently in people of Chinese (Han ethnic group), Thai, or Korean origin. Chronic kidney disease may also increase the risk in these patients.
If a rash or skin symptoms occur, stop taking allopurinol immediately and contact your doctor.
In cancer or Lesch-Nyhan syndrome, the amount of uric acid in the urine may increase. To prevent this, ensure adequate hydration of the patient to dilute the urine.
If you have kidney stones, they may decrease in size and enter the urinary tract.
Taking Adnamil in children is rarely indicated, except for certain types of cancer (especially leukemia) and certain enzymatic disorders, such as Lesch-Nyhan syndrome.
Tell your doctor or pharmacist about all medicines you are taking now or have recently taken, as well as any medicines you plan to take. This includes medicines available without a prescription, including herbal medicines. This is because Adnamil may affect the way some medicines work. Also, some other medicines may affect the way Adnamil works.
Tell your doctor or pharmacist if you are taking any of the following medicines:
If you are taking aluminum hydroxide, allopurinol may have a reduced effect.
Keep a gap of at least 3 hours between taking both medicines.
Blood disorders occur more frequently when allopurinol is taken with cytostatics (e.g., cyclophosphamide, doxorubicin, bleomycin, procarbazine, alkyl halides) than when these active substances are taken alone. Therefore, regular blood morphology tests should be performed.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to have a child, consult your doctor or pharmacist before taking this medicine.
Allopurinol passes into breast milk. It is not recommended to take this medicine during breastfeeding.
Drowsiness, dizziness, or coordination problems may occur. If such symptoms occur, do not drive or operate machinery.
If you have been diagnosed with intolerance to some sugars, consult your doctor before taking the medicine.
The medicine contains less than 1 mmol (23 mg) of sodium per tablet, which means it is considered "sodium-free".
The medicine may cause allergic reactions.
Take this medicine always as directed by your doctor. If you are unsure, consult your doctor or pharmacist.
Method of administration
Adnamil should be taken orally, once a day, after a meal, with a glass of water.
Usual doses range from 100 to 900 mg per day. Treatment can start with a small dose of the medicine, and then, if necessary, it can be increased.
In elderly patients or patients with kidney or liver problems, the doctor usually uses a lower dose or recommends taking the medicine less often than once a day.
In the case of patients undergoing dialysis two or three times a week, the doctor may recommend taking the medicine in a dose of 300 or 400 mg per day, which is taken immediately after dialysis.
Usual doses range from 100 to 400 mg per day.
If you have taken a higher dose of Adnamil than recommended, contact your doctor or go to the hospital immediately. Show the doctor the package with the tablets.
Symptoms of overdose may include nausea, vomiting, diarrhea, and dizziness.
If you miss a dose, take the next prescribed dose as soon as possible.
If it is almost time for the next dose, skip the missed dose.
Do not take a double dose to make up for the missed dose.
Do not stop treatment without consulting your doctor.
If you have any further questions about the use of this medicine, ask your doctor or pharmacist.
Like all medicines, Adnamil can cause side effects, although not everybody gets them.
The following side effects may occur during treatment with Adnamil:
Uncommon(may affect up to 1 in 100 people):
In case of hypersensitivity reaction (allergic), stop taking Adnamil immediately and contact your doctor. Symptoms may include:
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
In such cases, do not continue treatment unless your doctor advises otherwise.
Common(may affect up to 1 in 10 people):
Uncommon(may affect up to 1 in 100 people):
Rare(may affect up to 1 in 1,000 people):
Very rare(may affect up to 1 in 10,000 people):
Reporting side effects
If you experience any side effects, including those not listed in this leaflet, please tell your doctor or pharmacist, or nurse. Side effects can be reported directly to the Department of Drug Safety, Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Jerozolimskie Avenue 181C
02-222 Warsaw
Phone: +48 22 49 21 301
Fax: +48 22 49 21 309
Website: https://smz.ezdrowie.gov.pl
Side effects can also be reported to the marketing authorization holder.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep the medicine out of the sight and reach of children.
There are no special storage instructions for the medicine.
Do not use this medicine after the expiry date stated on the carton and blister after: "EXP". The expiry date refers to the last day of the month.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Adnamil 100 mg, white or almost white, round, biconvex, uncoated tablets, with "AL" and "100" engraved on one side, separated by a score line, and smooth on the other side.
The score line on the tablet is only to facilitate breaking and not to divide into equal doses.
PVDC/PVC/Aluminum blister pack in a cardboard box.
The pack contains 50 tablets and an information leaflet.
Adnamil 300 mg, peach-colored, round, biconvex, uncoated tablets, with "AL" and "300" engraved on one side, separated by a score line, and smooth on the other side.
The score line on the tablet is only to facilitate breaking and not to divide into equal doses.
PVDC/PVC/Aluminum blister pack in a cardboard box.
The pack contains 30 tablets and an information leaflet.
Polfarmex S.A.
Józefów 9
99-300 Kutno
Poland (Poland)
Phone: +48 24 357 44 44
Fax: +48 24 357 45 45
e-mail: polfarmex@polfarmex.pl
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.